ADC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH REGISTER
[Advanced]

The most recent version of this article was published on 1 July 2008

Arch Dis Child. Published Online First: 1 April 2008. doi:10.1136/adc.2007.128611
Copyright © 2008 BMJ Publishing Group Ltd & Royal College of Paediatrics and Child Health

This Article
Right arrow Full Text (Rapid PDF)
Right arrow All Versions of this Article:
adc.2007.128611v1
93/7/590    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in ADC Online
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Briars, G. L
Right arrow Articles by Kelly, A. M
PubMed
Right arrow PubMed Citation
Right arrow Articles by Briars, G. L
Right arrow Articles by Kelly, A. M

Original articles

Weight gain with Pizotifen therapy

Graham L Briars 1*, Sarah E Travis 1, Binu Anand 1 and Anne M Kelly 1

1 West Suffolk Hospital, United Kingdom

* To whom correspondence should be addressed. E-mail: g.briars{at}doctors.org.uk.

Accepted 8 March 2008


*   Abstract

Objective: To describe the characteristics of weight gain occurring on children treated for migranous conditions with pizotifen.

Design: Retrospective case note review

Setting: West Suffolk Hospital between 1999 and 2003

Patients: 405 clinic attendances of 121 children receiving Pizotifen treatment

Main outcome measures: Rates of change in weight for age z-score between successive outpatient appointments were used to detect excessive weight gain.

Results: The mean rate of weight z-score increase for 105 patients receiving a constant dosage in 181 intervals between appointments was 0.79 standard deviations per year compared with 0.11 standard deviations per year for height z-score increases. The rate of weight z-score increase was not correlated with pizotifen dose per kg (r-.0.08), per m2 (r=-0.05) or initial BMI (r=-0.04). Mean rates of z-score increase were similar in patients with a satisfactory and unsatisfactory therapeutic responses.

Conclusions: Excess weight gain in Pizotifen therapy is not predicted by drug dosage or therapeutic response within the range of doses used in clinical practice.








HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH REGISTER
ARCH DIS CHILD FETAL NEONATAL ED ED PRACTICE
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2008 BMJ Publishing Group Ltd & Royal College of Paediatrics and Child Health